Closing Remarks on Treating Patients with HR+ Breast Cancer
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.
Treatment after Progression on CDK4/6 Inhibitors
A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.
The Role of Surgery in Breast Cancer
Experts in oncology consider when surgery is appropriate for patients with breast cancer.
Overview of Treatment Options for Patients with Breast Cancer
Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.
Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.
Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer
Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.
Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer
Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.
Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer
Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.
HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification
Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.
HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts
Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.
Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer
Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.
Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents
Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.
Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy
Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.
Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC
Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.
HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors
A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.
Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer
HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors
Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.
MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant
Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.
MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy
Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.
PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy
Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.
Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer
Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.
HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium
Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.
Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer
Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.
Update on Novel Drug Targets in Metastatic Breast Cancer
More recently, researchers seek to understand the mechanisms related to tumor dissemination in hopes of therapeutically targeting this process.
Dr Deek on the Investigation of Immune Cell Infiltration in MIBC
Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer
Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma
Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer
2 Clarke Drive Cranbury, NJ 08512